← Back to Search
Myotax: A Phase II Trial Of Docetaxel Plus Non-pegylated Liposomal Doxorubicin As First-line Therapy Of Metastatic Breast Cancer Previously Treated With Adjuvant Anthracyclines.
E. Curtit, P. Nouyrigat, N. Dohollou, E. Levy, A. Lortholary, J. Gligorov, T. Facchini, D. Jaubert, N. Maille, X. Pivot, V. Grangé, L. Cals
Published 2011 · Medicine
Download PDFAnalyze on Scholarcy
AIM Non-pegylated liposomal doxorubicin (NPLD) has demonstrated equivalent antitumour activity to conventional doxorubicin and a significantly lower risk of cardiotoxicity when given as a single agent or in combination with cyclophosphamide. This phase II trial was performed to evaluate the efficacy and the safety of NPLD and docetaxel combination in patients with metastatic breast cancer previously exposed to adjuvant anthracyclines. PATIENTS AND METHODS Thirty-four patients received NPLD 60 mg/m(2) and docetaxel 75 mg/m(2) in a 21-day cycle as first-line therapy of metastatic breast cancer. Treatment was planned for six cycles and was continued until progression or toxicity. RESULTS Objective response rate among response-assessable patients was 79% (95% CI (confidence interval), 64-94%) and 27% (95% CI, 11-43%) presented a complete response. Median progression free survival was 11.3 months (95% CI, 6.2-13.3 months) and median overall survival was 28.2 months (95% CI, 16-36.4 months). Symptomatic grade 3 cardiotoxicity occurred in 15% of cases and febrile neutropenia in 47% of the patients. CONCLUSIONS The combination of NPLD and docetaxel demonstrated high antitumour activity in a population of metastatic breast cancer patients exposed to adjuvant anthracyclines and showed an unexpected and unexplained 15% symptomatic left ventricular systolic dysfunction rate.
This paper references
Improved anti-tumor response rate with decreased cardiotoxicity of non-pegylated liposomal doxorubicin compared with conventional doxorubicin in first-line treatment of metastatic breast cancer in patients who had received prior adjuvant doxorubicin: results of a retrospective analysis
G. Batist (2006)
Phase III trial of doxorubicin, paclitaxel, and the combination of doxorubicin and paclitaxel as front-line chemotherapy for metastatic breast cancer: an intergroup trial (E1193).
G. Sledge (2003)
Phase I study of weekly paclitaxel and liposomal doxorubicin in patients with advanced solid tumours.
N. Androulakis (2002)
A unified definition of clinical anthracycline resistance breast cancer
X. Pivot (2000)
Taxane-based combinations as adjuvant chemotherapy of early breast cancer: a meta-analysis of randomized trials.
M. De Laurentiis (2008)
Phase II study of docetaxel, doxorubicin, and cyclophosphamide as first-line chemotherapy for metastatic breast cancer.
J. Nabholtz (2001)
Doxorubicin and paclitaxel versus fluorouracil, doxorubicin, and cyclophosphamide as first-line therapy for women with metastatic breast cancer: final results of a randomized phase III multicenter trial.
J. Jassem (2001)
First line therapy with paclitaxel (Taxol) and pegylated liposomal doxorubicin (Caelyx) in patients with metastatic breast cancer: a multicentre phase II study.
D. Vorobiof (2004)
Epirubicin and cyclophosphamide versus epirubicin and docetaxel as first-line therapy for women with metastatic breast cancer: final results of a randomised phase III trial.
J. Blohmer (2010)
Effects of chemotherapy and hormonal therapy for early breast cancer on recurrence and 15-year survival: an overview of the randomised trials
O. Abe (2005)
Prospects with docetaxel in the treatment of patients with breast cancer.
M. Marty (1997)
What's going on 乳癌 Effects of chemotherapy and hormonal therapy for early breast cancer on recurrence and 15-year survival: an overview of the randomised trials. Early Breast Cancer Trialists' Collaborative Group(EBCTCG). Lancet. 2005; 365: 1687-717. PMID: 15894097.--早期乳癌に対する化学療法・内分泌療法が乳癌再発・15年生存率に及
青儀 健二郎 (2006)
Taxanebased combinations as adjuvant chemotherapy of early breast cancer: a meta-analysis of randomized trials
M De Laurentiis (2008)
First line chemotherapy of metastatic breast cancer.
P. Pronzato (2006)
Non-pegylated liposomal doxorubicin and docetaxel in metastatic breast cancer: final results of a phase II trial
P. Schmid (2008)
Global Cancer Statistics, 2002
D. Parkin (2005)
Dose-finding study of docetaxel and doxorubicin in first-line treatment of patients with metastatic breast cancer.
J. L. Misset (1999)
Expert opinion on the use of anthracyclines in patients with advanced breast cancer at cardiac risk.
P. Barrett-Lee (2009)
Doxorubicin and paclitaxel versus doxorubicin and cyclophosphamide as first-line chemotherapy in metastatic breast cancer: The European Organization for Research and Treatment of Cancer 10961 Multicenter Phase III Trial.
L. Biganzoli (2002)
Docetaxel and pegylated liposomal doxorubicin combination as first-line therapy for metastatic breast cancer patients: results of the phase II GINECO trial CAPYTTOLE.
C. de la Fouchardiere (2009)
Liposome‐encapsulated doxorubicin compared with conventional doxorubicin in a randomized multicenter trial as first‐line therapy of metastatic breast carcinoma
L. Harris (2002)
Phase II multicentre randomised study of docetaxel plus epirubicin vs 5-fluorouracil plus epirubicin and cyclophosphamide in metastatic breast cancer
J. Bonneterre (2004)
Phase II multicenter trial of anthracycline rechallenge with pegylated liposomal doxorubicin plus cyclophosphamide for first-line therapy of metastatic breast cancer previously treated with adjuvant anthracyclines.
M. Trudeau (2009)
A multicentre phase II study of cisplatin and gemcitabine for malignant mesothelioma
A. Nowak (2002)
Phase II to III study comparing doxorubicin and docetaxel with fluorouracil, doxorubicin, and cyclophosphamide as first-line chemotherapy in patients with metastatic breast cancer: results of a Dutch Community Setting Trial for the Clinical Trial Group of the Comprehensive Cancer Centre.
M. Bontenbal (2005)
Reduced cardiotoxicity and preserved antitumor efficacy of liposome-encapsulated doxorubicin and cyclophosphamide compared with conventional doxorubicin and cyclophosphamide in a randomized, multicenter trial of metastatic breast cancer.
G. Batist (2001)
A randomised phase II study of two different schedules of pegylated liposomal doxorubicin in metastatic breast cancer (EORTC-10993).
R. Coleman (2006)
First line therapy with paclitaxel ( Taxol ) and pegylated liposomal doxorubicin ( Caelyx ) in patients with metastatic
Anthracyclines in the Treatment of Cancer
G. Hortobagyi (2012)
Docetaxel and doxorubicin compared with doxorubicin and cyclophosphamide as first-line chemotherapy for metastatic breast cancer: results of a randomized, multicenter, phase III trial.
J. Nabholtz (2003)
Phase III trial of liposomal doxorubicin and cyclophosphamide compared with epirubicin and cyclophosphamide as first-line therapy for metastatic breast cancer.
S. Chan (2004)
Non-pegylated liposomal doxorubicin in metastatic breast cancer patients: a valuable therapeutic option requiring caution.
D. Bernardi (2010)
Cardiac function following combination therapy with paclitaxel and doxorubicin: an analysis of 657 women with advanced breast cancer.
L. Gianni (2001)
A multicentre Phase II study of non-pegylated liposomal doxorubicin in combination with trastuzumab and docetaxel as first-line therapy in metastatic breast cancer.
M. Venturini (2010)
Corticosteroids significantly delay the onset of docetaxel-induced fluid retention: final results of a randomized study of the European Organization for Research and Treatment of Cancer Investigational Drug Branch for Breast Cancer.
M. Piccart (1997)
Cytotoxic and hormonal treatment for metastatic breast cancer: a systematic review of published randomized trials involving 31,510 women.
R. Fossati (1998)
Anthracyclines in the treatment of cancer. An overview.
G. Hortobagyi (1997)
Weekly combination of non-pegylated liposomal doxorubicin and taxane in first-line breast cancer: wALT trial (phase I-II).
M. S. Rosati (2011)
Single agent versus combination chemotherapy for metastatic breast cancer.
S. Carrick (2009)
Global cancer statistics
A. Jemal (2011)
This paper is referenced by
The Role of Liposomal Anthracyclines in Metastatic Breast Cancer
A. Gennari (2013)
Liposomal Doxorubicin in the Treatment of Breast Cancer Patients: A Review
J. Lao (2013)
Antimicrobial peptides, nanotechnology, and natural metabolites as novel approaches for cancer treatment
M. Leite (2018)
Pegylated liposomal doxorubicin (Lipo-Dox®) combined with cyclophosphamide and 5-fluorouracil is effective and safe as salvage chemotherapy in taxane-treated metastatic breast cancer: an open-label, multi-center, non-comparative phase II study
K. Rau (2015)
Tumoren der Lunge (2012)
Cáncer de mama metastásico
P. Beuzeboc (2015)
Current status of nanomedicine in the chemotherapy of breast cancer
A. I. Fraguas-Sánchez (2019)
Clinical Translation of Self‐Assembled Cancer Nanomedicines
P. Mi (2020)
Nicht pegyliertes liposomales Doxorubicin doch nicht weniger kardiotoxisch?
J. Neumaier (2012)
Topoisomerase Inhibitors in Metastatic Breast Cancer: Overview of Current Practice and Future Development
Marie-Catherine Vanderbeeken (2013)
Non-Pegylated Liposomal Doxorubicin-Cyclophosphamide in Sequential Regimens with Taxanes as Neoadjuvant Chemotherapy in Breast Cancer Patients
P. Vici (2014)